Eli Lilly and Company

Alexei Pavlovych Krasutsky

Owen Brendan Wallace

Yanping Xu

Nancy June Snyder

Jeremy Schulenburg York

Thomas Daniel Aicher

Leonard Larry Winneroski, Jr

Renhua Li

Ashraf Saeed

Thomas Edward Mabry

Ronald Jay Hinklin

John Gordon Allen

Jefferson Ray McCowan

Peter Biagio Anzeveno

Gregory Alan Stephenson

Zhaogen Chen

Gary A Hite

James Lee Toth

Hongqi Tian

Leonard Larry Junior Winneroski

Gary Alan Hite

Junior Leonard Larry Winneroski

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: (I) possessing 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Growing community of inventors

Zionsville, IN, United States of America

Alexei Pavlovych Krasutsky